An education-behavioural intervention improves adherence to statins

• Authors: Przemyslaw Kardas
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Patient adherence; Statins; Hyperlipidemia; Education-behavioural intervention; Primary prevention; Secondary prevention

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 5
• Pages: 580-585

Dates

published

1 - 10 - 2013

online

18 - 9 - 2013

Contributors

author

Przemyslaw Kardas

• Department of Family Medicine, Medical University of Lodz, 60, Narutowicza Str., 90-136, Lodz, Poland

References

• [1] Sabate E (red). Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003
• [2] Kardas P. Compliance, Clinical Outcome, And Quality Of Life Of Patients With Stable Angina Pectoris Receiving Once Daily Betaxolol Versus Twice Daily Metoprolol: A Randomized Controlled Trial. Vas Health Risk Manag 2007;3(2): 235–242 http://dx.doi.org/10.2147/vhrm.2007.3.2.235[Crossref]
• [3] Kardas P. Comparison Of Once Daily Versus Twice Daily Oral Nitrates In Stable Angina Pectoris. Am J Cardiol 2004;94: 213–216 http://dx.doi.org/10.1016/j.amjcard.2004.03.067[Crossref]
• [4] Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10): 1013–1024 http://dx.doi.org/10.1007/s00228-009-0673-0[WoS][Crossref]
• [5] Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2): 177–186 http://dx.doi.org/10.1001/jama.297.2.177[Crossref]
• [6] Poluzzi E, Piccinni C, Carta P et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol. 2011;67(4): 407–414 http://dx.doi.org/10.1007/s00228-010-0958-3[WoS][Crossref]
• [7] Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perrault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharacol 2007;63(6): 698–708 http://dx.doi.org/10.1111/j.1365-2125.2006.02828.x[Crossref]
• [8] Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006; 6: 48., doi:10.1186/1471-2261-6-48 http://dx.doi.org/10.1186/1471-2261-6-48[Crossref]
• [9] Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165(10): 1147–1152 http://dx.doi.org/10.1001/archinte.165.10.1147[Crossref]
• [10] Rublee DA, Chen SY, Mardekian J, Wu N, Rao P, Boulanger L. Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Am J Ther. 2012;19(1): 24–32 http://dx.doi.org/10.1097/MJT.0b013e3181ee707e[Crossref]
• [11] Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy - experience in Australia 2006–2010. Aust Fam Physician. 2011;40(5): 319–322
• [12] McGinnis BD, Olson KL, Delate TM, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care. 2009;15(10): 689–695
• [13] Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009;169(3): 260–268 http://dx.doi.org/10.1001/archinternmed.2008.552[Crossref]
• [14] Peterson AM, Takiya L, Finley R. Meta-analysis of interventions to improve drug adherence in patients with hyperlipidemia. Pharmacotherapy. 2003;23(1): 80–87 http://dx.doi.org/10.1592/phco.23.1.80.31921[Crossref]
• [15] Kardas P. Prevalence and reasons for non-adherence to hyperlipidemia treatment. Submitted to Centr Eur J Med, 2013 [WoS]
• [16] Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Submitted to Front Pharmacol. 2013
• [17] DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3): 200–209 http://dx.doi.org/10.1097/01.mlr.0000114908.90348.f9[Crossref]
• [18] Konduracka E, Jozwiak J, Mastej M et al. Rozpowszechnienie i niska skutecznosc leczenia dyslipidemii w prewencji pierwotnej i wtornej choroby niedokrwiennej serca na poziomie lekarzy medycyny rodzinnej - wyniki ogolnopolskiego badania epidemiologicznego LIPIDOGRAM 2004. Przegl Lek 2008;65(12): 834–837
• [19] Grzelak-Hodor J. Brak compliance w leczeniu statynami. Puls Medycyny 19(202), 2009
• [20] Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; (2): CD000011 [WoS]
• [21] Nieuwkerk PT, Nierman MC, Vissers MN, Locadia M, Greggers-Peusch P, Knape LP, Kastelein JJ, Sprangers MA, de Haes HC, Stroes ES. Intervention to Improve Adherence to Lipid-Lowering Medication and Lipid-Levels in Patients With an Increased Cardiovascular Risk. Am J Cardiol. 2012 Sep 1;110(5):666–672 http://dx.doi.org/10.1016/j.amjcard.2012.04.045[Crossref]
• [22] Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J. 2012; 163(4): 657–665.e1 http://dx.doi.org/10.1016/j.ahj.2012.01.019[Crossref]
• [23] Eussen SR, van der Elst ME, Klungel OH, Rompelberg CJ, Garssen J, Oosterveld MH, de Boer A, de Gier JJ, Bouvy ML. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Ann Pharmacother. 2010; 44(12): 1905–1913 http://dx.doi.org/10.1345/aph.1P281[Crossref]
• [24] Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. Patient Prefer Adherence. 2012; 6: 323–329 http://dx.doi.org/10.2147/PPA.S29353[Crossref]
• [25] Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010; (3): CD004371 [WoS]
• [26] Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens. 1993; 11(12): 1403–1411 http://dx.doi.org/10.1097/00004872-199312000-00013[Crossref]
• [27] Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–467 http://dx.doi.org/10.1001/jama.288.4.462[Crossref]
• [28] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011; 30(1): 91–99 http://dx.doi.org/10.1377/hlthaff.2009.1087[Crossref]

Identifiers

DOI

10.2478/s11536-013-0170-9